RPG LIFESCIENCES LTD
RESULTS FOR Q4 FY 2013
RPG LIFESCIENCES LTD has performed well in Q4 FY 2013 compared to
the preceding and corresponding Quarters.
Net Sales for Q4 FY 13 stands at Rs.56.34 Cr; compared to Rs.48.09
cr in the preceding Qtr of Q3 FY 13 ( + 17.16% ); and compared to Rs.41.23 cr
in the corresponding quarter of Q4 FY 13 (+36.65%). Net Sales has improved
reasonably well in Q4.
Total Expenditure for Q4 FY 13 stands at Rs.53.72 Cr; compared to
Rs.53.88 cr in the preceding Qtr of Q3 FY 13 ( -0.3% ); and compared to Rs.47.45
cr in the corresponding quarter of Q4 FY 13 (+13.21%). Total expenditure has
gone up less than proportionately compared to Net Sales.
Total Income for Q4 FY 13
stands at Rs.58.41 Cr; compared to Rs.49.01 cr in the preceding Qtr of Q3 FY 13
( +19.18% ); and compared to Rs.42.20 cr in the corresponding quarter of Q4 FY
13 (+38.41%). Total Income has gone up impressively both QoQ and YoY.
Cost of materials for Q4 FY
13 stands at Rs.12.12 Cr; compared to Rs.13.59 cr in the preceding Qtr of Q3 FY
13 ( -10.82% ); and compared to Rs.9.31cr in the corresponding quarter of Q4 FY
13 (+30.18%). Cost of Materials has gone up significantly, though less than
proportionately with the Net Sales.
Purchases of SIT for Q4 FY 13 stands at Rs.4.25 Cr; compared to
Rs.4.11 cr in the preceding Qtr of Q3 FY 13 ( +3.41% ); and compared to Rs.3.54 cr in the corresponding quarter of
Q4 FY 13 (+20.06%).
Employee benefits for
Q4 FY 13 stands at Rs.13.51 Cr; compared to Rs.13.91 cr in the preceding Qtr of
Q3 FY 13 ( -2.88% ); and compared to Rs.12.24 cr in the corresponding quarter
of Q4 FY 13 (+10.38%).
Depreciation for Q4 FY 13
stands at Rs.2.53 Cr; compared to Rs.2.57 cr in the preceding Qtr of Q3 FY 13 (
-1.56% ); and compared to Rs.2.60 cr
in the corresponding quarter of Q4 FY 13 (-2.69%).
Other expenses for Q4 FY 13
stands at Rs.16.90 Cr; compared to Rs.19.30 cr in the preceding Qtr of Q3 FY 13
( -12.44% ); and compared to Rs.17.82cr in the corresponding quarter of Q4 FY
13 (-5.16%).
Total expenses for Q4 FY 13
stands at Rs.53.72 Cr; compared to Rs.53.88 cr in the preceding Qtr of Q3 FY 13
( -0.3% ); and compared to Rs.47.45cr in the corresponding quarter of Q4 FY 13
(+13.21%). Expenses are thus under reasonable control.
Profit before tax for Q4 FY 13 stands at Rs.3.53 Cr;
compared to Rs.(-)6.35 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)6.43 cr in the corresponding quarter of Q4
FY 13. At the PBT stage also, the improvement is significant.
Tax Expenses for Q4 FY 13 stands at Rs.(-)3.87 Cr;
compared to Rs.(-)0.26 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)0.74cr
in the corresponding quarter of Q4 FY 13. The lower Tax expenses has
significantly enhance the net Profits.
Net Profit for Q4 FY 13 stands at Rs.7.40 Cr;
compared to Rs.(-)6.09 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)5.69cr
in the corresponding quarter of Q4 FY 13. Net Profit has improved decisively
and significantly in the 4th quarter.
Face Value of
Share is Rs.8.
Paid-up Equity stands at Rs.13.23 Cr.
Basic EPS for Q4
FY 13 stands at Rs.4.48; compared to Rs(-)3.68 in the preceding quarter and Rs.(-)3.44
in the corresponding quarter. This is a significant improvement over both the
preceding and corresponding quarters.
Public holding in
the company stands at 43.52%.
The improvement in the performance
of RPG Lifesciences in Q4 is very good. RPGLIF is acquiring more and more
approvals for its products and for its factories, which is good for its long
term performance.
*
* * E
N D *
* *
